Literature DB >> 23160178

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene.

Tara Ann Burns1, Marimuthu Subathra, Paola Signorelli, Young Choi, Xiaofeng Yang, Yong Wang, Maristella Villani, Kapil Bhalla, Daohong Zhou, Chiara Luberto.   

Abstract

Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation. To examine if dysregulated SMS contributes to leukemogenesis, we measured SMS activity in several leukemic cell lines and found that it is highly elevated in K562 chronic myelogenous leukemia (CML) cells. The increased SMS in K562 cells was caused by the presence of Bcr-abl, a hallmark of CML; stable expression of Bcr-abl elevated SMS activity in HL-60 cells while inhibition of the tyrosine kinase activity of Bcr-abl with Imatinib mesylate decreased SMS activity in K562 cells. The increased SMS activity was the result of up-regulation of the Sms1 isoform. Inhibition of SMS activity with D609 (a pharmacological SMS inhibitor) or down-regulation of SMS1 expression by siRNA selectively inhibited the proliferation of Bcr-abl-positive cells. The inhibition was associated with an increased production of ceramide and a decreased production of DAG, conditions that antagonize cell proliferation. A similar change in lipid profile was also observed upon pharmacological inhibition of Bcr-abl (K526 cells) and siRNA-mediated down-regulation of BCR-ABL (HL-60/Bcr-abl cells). These findings indicate that Sms1 is a downstream target of Bcr-abl, involved in sustaining cell proliferation of Bcr-abl-positive cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160178      PMCID: PMC3617953          DOI: 10.1194/jlr.M033985

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  60 in total

1.  Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.

Authors:  H M Kantarjian; R S Walters; M J Keating; M Talpaz; B Andersson; M Beran; K B McCredie; E J Freireich
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

2.  The synthesis of sphingomyelin in the Morris hepatomas 7777 and 5123D is restricted to the plasma membrane.

Authors:  A van den Hill; G P van Heusden; K W Wirtz
Journal:  Biochim Biophys Acta       Date:  1985-02-08

3.  Stimulation of sphingomyelin biosynthesis by brefeldin A and sphingomyelin breakdown by okadaic acid treatment of rat hepatocytes.

Authors:  G M Hatch; D E Vance
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

Review 4.  An update of the enzymology and regulation of sphingomyelin metabolism.

Authors:  A H Merrill; D D Jones
Journal:  Biochim Biophys Acta       Date:  1990-05-01

5.  Cellular and enzymic synthesis of sphingomyelin.

Authors:  D R Voelker; E P Kennedy
Journal:  Biochemistry       Date:  1982-05-25       Impact factor: 3.162

6.  Programmed cell death induced by ceramide.

Authors:  L M Obeid; C M Linardic; L A Karolak; Y A Hannun
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.

Authors:  E Bonhoure; A Lauret; D J Barnes; C Martin; B Malavaud; T Kohama; J V Melo; O Cuvillier
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

8.  Microsomal sphingomyelin accumulation in thioacetamide-injured regenerating rat liver: involvement of sphingomyelin synthase activity.

Authors:  M J Miró-Obradors; J Osada; H Aylagas; I Sánchez-Vegazo; E Palacios-Alaiz
Journal:  Carcinogenesis       Date:  1993-05       Impact factor: 4.944

9.  Biosynthesis of sphingomyelin from erythro-ceramides and phosphatidylcholine by a microsomal cholinephosphotransferase.

Authors:  J T Bernert; M D Ullman
Journal:  Biochim Biophys Acta       Date:  1981-10-23

10.  Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.

Authors:  H M Kantarjian; M Talpaz; D Kontoyiannis; J Gutterman; M J Keating; E H Estey; S O'Brien; M B Rios; M Beran; A Deisseroth
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

View more
  12 in total

1.  Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.

Authors:  Yun-Chi Tang; Hui Yuwen; Kaiying Wang; Peter M Bruno; Kevin Bullock; Amy Deik; Stefano Santaguida; Marianna Trakala; Sarah J Pfau; Na Zhong; Tao Huang; Lan Wang; Clary B Clish; Michael T Hemann; Angelika Amon
Journal:  Cancer Res       Date:  2017-08-03       Impact factor: 12.701

2.  Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.

Authors:  Sitapriya Moorthi; Tara Ann Burns; Gui-Qin Yu; Chiara Luberto
Journal:  FASEB J       Date:  2018-03-13       Impact factor: 5.191

3.  Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.

Authors:  Saïd Taouji; Arisa Higa; Frédéric Delom; Sandrine Palcy; François-Xavier Mahon; Jean-Max Pasquet; Roger Bossé; Bruno Ségui; Eric Chevet
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

4.  UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.

Authors:  Marthe-Susanna Wegner; Nina Schömel; Lisa Gruber; Stephanie Beatrice Örtel; Matti Aleksi Kjellberg; Peter Mattjus; Jennifer Kurz; Sandra Trautmann; Bing Peng; Martin Wegner; Manuel Kaulich; Robert Ahrends; Gerd Geisslinger; Sabine Grösch
Journal:  Cell Mol Life Sci       Date:  2018-03-17       Impact factor: 9.261

5.  Sphingomyelin synthase 2 overexpression promotes cisplatin-induced apoptosis of HepG2 cells.

Authors:  Si Luo; Zhen Pan; Shuang Liu; Shujing Yuan; Nianlong Yan
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

6.  Sphingomyelin Synthase 1 Regulates Neuro-2a Cell Proliferation and Cell Cycle Progression Through Modulation of p27 Expression and Akt Signaling.

Authors:  Umadevi V Wesley; James F Hatcher; Robert J Dempsey
Journal:  Mol Neurobiol       Date:  2014-08-02       Impact factor: 5.590

Review 7.  Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.

Authors:  Kazuyuki Kitatani; Makoto Taniguchi; Toshiro Okazaki
Journal:  Mol Cells       Date:  2015-05-22       Impact factor: 5.034

8.  Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.

Authors:  A Kilbey; A Terry; S Wotton; G Borland; Q Zhang; N Mackay; A McDonald; M Bell; M J O Wakelam; E R Cameron; J C Neil
Journal:  J Cell Biochem       Date:  2017-01-10       Impact factor: 4.429

9.  Regulation of human sphingomyelin synthase 1 translation through its 5'-untranslated region.

Authors:  Foysal Daian; Brecken Shenandoah Esper; Navid Ashrafi; Gui-Qin Yu; Gabriella Luciano; Sitapriya Moorthi; Chiara Luberto
Journal:  FEBS Lett       Date:  2020-10-31       Impact factor: 4.124

Review 10.  Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.

Authors:  Michela Codini; Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.